Abstract:Background: Multiple adjuvant treatment strategies are available for resected epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), but what is the preferred method among these strategies remain unsolved. Methods: A network meta-analysis was performed to investigate the efficacy and safety of targeted therapy, immunotherapy, and chemotherapy for resected EGFR-mutant NSCLC. Electronic databases were searched using relevant keywords. Randomized controlled trials comparing two adjuvant treatments for resected EGFR-mutant NSCLC patients were included. The primary endpoint was disease-free survival (DFS), and secondary endpoints were overall survival (OS) and grade ≥3 adverse events (AEs). Findings: Thirteen eligible trials involving 3300 patients and six treatment strategies were included. All EGFR-TKIs-based adjuvant therapies, including osimertinib (hazard ratio [HR]=0.23, 95% confidence interval [CI]: 0.16-0.33), chemotherapy followed by first-generation EGFR-TKI (Chemo-TKI; HR=0.34, 95% CI: 0.16-0.69), first-generation EGFR-TKIs (1st EGFR-TKI; HR=0.62, 95%CI: 0.52-0.74), can provide significant DFS benefits compared with chemotherapy for EGFR-mutant NSCLC patients. Adjuvant immunotherapy did not improve DFS compared with chemotherapy. (HR=0.98, 95% CI: 0.64-1.50). In patients who were treated with adjuvant 1st EGFR-TKI, previous chemotherapy did not improve the DFS (0.54, 0.26-1.14) and OS (0.83, 0.15-4.52) benefit. In addition, no OS improvements were identified when comparing all the EGFR-TKI-based treatments with chemotherapy (HR=0.76, 95% CI: 0.14-4.12 for Chemo-TKI; HR=0.94, 95% CI: 0.73-1.22 for EGFR-TKIs monotherapy). Osimertinib showed the fewest toxic effects, whereas Chemo-TKI caused the most toxicity. In subgroup analysis, patients with EGFR exon 19 deletion, stage III disease, and adenocarcinoma can benefit more from adjuvant EGFR-TKIs therapy. Interpretation: EGFR-TKIs-based adjuvant therapies can provide a significant DFS benefit compared with immunotherapy or chemotherapy for resected EGFR-mutant NSCLC, especially osimertinib. Adjuvant immunotherapy failed to show a DFS benefit versus chemotherapy. Adjuvant EGFR-TKIs could be an important treatment option for resected early-stage EGFR-mutant NSCLC, regardless of previous chemotherapy. Funding: None.Declaration of Interest: Yi-Long Wu reports consulting and advisory services and declares speaker fees for Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, Merck Sharp & Dohme,and Bristol Myers Squibb. All other authors declare that they have no conflict of interest.

Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis

EGFR-TKI-based Vs Non-Egfr-tki-based Adjuvant Therapy in Resected Non-Small-cell Lung Cancer with EGFR Mutations: a Meta-Analysis of Randomized Controlled Trials.

Epidermal Growth Factor Receptor Inhibitors As Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer Harboring EGFR Mutation: a Meta-Analysis of Randomized Controlled Clinical Trials

The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

Disease-free Survival Improved by Use of Adjuvant EGFR Tyrosine Kinase Inhibitors in Resectable Non-Small Cell Lung Cancer: an Updated Meta-Analysis.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

359P the Role of Adjuvant Targeted Therapy for Postoperative EGFR Mutant Non-Small Cell Lung Cancer: A Network Meta-Analysis

Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis

Comparison of Adjuvant Target Therapy, Immunotherapy, and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients

Adjuvant EGFR tyrosine kinase inhibitors for patients with resected <i>EGFR</i>-mutated non-small-cell lung cancer: a network meta-analysis

Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Comprehensive Study of Neoadjuvant Targeted Therapy for Resectable Non-Small Cell Lung Cancer

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials